Skip to content

Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension

(e-MOTION PH) Electronic - Activity Level Monitoring Pilot in Pulmonary Hypertension

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02536534
Acronym
e-MOTION PH
Enrollment
35
Registered
2015-09-01
Start date
2015-06-30
Completion date
2016-12-21
Last updated
2017-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Pulmonary

Keywords

Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Brief summary

Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) over 6 months in routine clinical practice settings.

Detailed description

Remote patient monitoring can lead to improved patient outcomes, including improved quality of life, reduced readmissions, earlier treatment for symptoms detected prior to schedule in-office follow-up visits, improved communications with care providers, increased participation in self-management of disease, and an improved knowledge of their medical conditions . In patients with PAH, daily activity level, as measured using a physical activity monitor for seven consecutive days, correlated with 6-minute walk distance (6MWD). The monitor used in the aforementioned PAH study was positioned on the patients' right upper arm with an armband, as opposed to the more popular and more comfortable wristbands used today, such as the Fitbit Flex. Although the aforementioned PAH study did show a correlation between activity level monitoring and 6MWD, the patients were monitored for only seven days. It is still unknown whether this correlation would exist over a longer trial period and whether patients, their caregivers, and clinicians would find activity level monitoring useful in helping manage PH.

Interventions

Sponsors

Bayer
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female patients with a diagnosis of Pulmonary Arterial Hypertension (PAH); or inoperable, persistent or recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH), * Age ≥ 18 years, * Baseline 6 Minute Walk Distance (6MWD) a minimum of 250 meters or maximum 450 meters, (ensure significant Pulmonary Hypertension(PH) without limiting their participation in the trial) * WHO Functional Class II or III, * Clinically stable patient defined as within the last 12 months (minimum of 3 months) prior to enrollment, there was no: * decline in World Health Organization (WHO) Function class or, * decline in 6MWD by 15% or, * change of oral PAH/CTEPH therapy (may have flexible diuretics/anticoagulation) or, * Introduction of parenteral Prostacyclin Analog (PCA) treatment. * Patients provide written informed consent, are able to understand and follow instructions.

Exclusion criteria

* Hypersensitivity to nickel (present in the clasp of the FitBit Flex's band), * Medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator, * Enrolled in pulmonary rehabilitation program within last 6 months, * Participating in an interventional study.

Design outcomes

Primary

MeasureTime frameDescription
6-minute walk distance (6MWD)At baseline(performed by investigator)
Number of steps per dayAt baseline(monitored by Fitbit Flex)

Secondary

MeasureTime frame
Change in World Health Organization (WHO) functional Class recorded by investigator in conjunction with the 6MWDAt baseline, 3 months and 6 months
Change in Borg Dyspnea value recorded by investigator in conjunction with the 6MWDAt baseline, 3 months and 6 months
Change in quality of life recorded by patient questionnaire Living with Pulmonary hypertension Questionnaire (LPH)At baseline, 3 months and 6 months
Caregiver Satisfaction and Usability questionnaireAt 3 months and 6 months
Patient Satisfaction and Usability questionnaireAt 3 months and 6 months
Healthcare provider Satisfaction and Usability questionnaireAt 3 months and 6 months
Change in compliance with medication using the Moriky´s QuestionnaireAt baseline, 3 months and 6 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026